scholarly journals Post-Lumpectomy Breast Radiation Lowers IBR for “Good Risk” DCIS

2022 ◽  
Vol 44 (1) ◽  
pp. 30-30
Author(s):  
Mark McGraw
Keyword(s):  
Good Risk

Chemotherapy for good-risk germ-cell tumors

2002 ◽  
Vol 20 (4) ◽  
pp. 244-250 ◽  
Author(s):  
Charles J. Ryan ◽  
Dean F. Bajorin
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumors ◽  
Good Risk

scholarly journals Copy Number Alteration Profile Provides Additional Prognostic Value for Acute Lymphoblastic Leukemia Patients Treated on BFM Protocols

Cancers ◽  
2021 ◽  
Vol 13 (13) ◽  
pp. 3289
Author(s):  
Μirella Αmpatzidou ◽  
Lina Florentin ◽  
Vassilios Papadakis ◽  
Georgios Paterakis ◽  
Marianna Tzanoudaki ◽  
...  
Keyword(s):  
Risk Stratification ◽  
Copy Number ◽  
Copy Number Alteration ◽  
Lymphoblastic Leukemia ◽  
Risk Index ◽  
Outcome Predictor ◽  
Distinct Subgroup ◽  
Genomic Risk ◽  
Good Risk

We present our data of a novel proposed CNA-profile risk-index, applied on a Greek ALLIC-BFM-treated cohort, aiming at further refining genomic risk-stratification. Eighty-five of 227 consecutively treated ALL patients were analyzed for the copy-number-status of eight genes (IKZF1/CDKN2A/2B/PAR1/BTG1/EBF1/PAX5/ETV6/RB1). Using the MLPA-assay, patients were stratified as: (1) Good-risk(GR)-CNA-profile (n = 51), with no deletion of IKZF1/CDKN2A/B/PAR1/BTG1/EBF1/PAX5/ETV6/RB1 or isolated deletions of ETV6/PAX5/BTG1 or ETV6 deletions with a single additional deletion of BTG1/PAX5/CDKN2A/B. (2) Poor-risk(PR)-CNA-profile (n = 34), with any deletion of ΙΚΖF1/PAR1/EBF1/RB1 or any other CΝΑ. With a median follow-up time of 49.9 months, EFS for GR-CNA-profile and PR-CNA-profile patients was 96.0% vs. 57.6% (p < 0.001). For IR-group and HR-group patients, EFS for the GR-CNA/PR-CNA subgroups was 100.0% vs. 60.0% (p < 0.001) and 88.2% vs. 55.6% (p = 0.047), respectively. Among FC-MRDd15 + patients (MRDd15 ≥ 10−4), EFS rates were 95.3% vs. 51.7% for GR-CNA/PR-CNA subjects (p < 0.001). Similarly, among FC-MRDd33 + patients (MRDd33 ≥ 10−4), EFS was 92.9% vs. 27.3% (p < 0.001) and for patients FC-MRDd33 − (MRDd33 < 10−4), EFS was 97.2% vs. 72.7% (p = 0.004), for GR-CNA/PR-CNA patients, respectively. In a multivariate analysis, the CNA-profile was the most important outcome predictor. In conclusion, the CNA-profile can establish a new genomic risk-index, identifying a distinct subgroup with increased relapse risk among the IR-group, as well as a subgroup of patients with superior prognosis among HR-patients. The CNA-profile is feasible in BFM-based protocols, further refining MRD-based risk-stratification.

Reassessment of 4-Cycle Etoposide and Cisplatin as the Standard of Care for Good-Risk Metastatic Germ Cell Tumors

JAMA Oncology ◽  
2018 ◽  
Vol 4 (12) ◽  
pp. 1661 ◽  
Author(s):  
Daniel E. Fein ◽  
Jessica K. Paulus ◽  
Paul Mathew
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumors ◽  
Standard Of Care ◽  
Good Risk

Nimodipine treatment of selected good-risk patients with subarachnoid hemorrhage: No significant difference between present and historical results

1988 ◽  
Vol 30 (3) ◽  
pp. 180-186 ◽  
Author(s):  
Luigi Pellettieri ◽  
Hans Bolander ◽  
Hans Carlsson ◽  
Ulf Sjölander
Keyword(s):  
Subarachnoid Hemorrhage ◽  
Significant Difference ◽  
Risk Patients ◽  
Good Risk

Testicular Germ Cell Tumors in Adolescents – Results of the Protocol MAHO 98 and the Identification of Good Risk Patients

2014 ◽  
Vol 226 (06/07) ◽  
pp. 316-322 ◽  
Author(s):  
U. Göbel ◽  
G. Calaminus ◽  
R. Haas ◽  
C. Teske ◽  
S. Schönberger ◽  
...  
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumors ◽  
Testicular Germ Cell Tumors ◽  
Testicular Germ Cell ◽  
Risk Patients ◽  
Good Risk
Sign in / Sign up

Export Citation Format

Share Document